Global Blood Therapeutics, Inc. (GBT)
(Delayed Data from NSDQ)
$55.18 USD
+1.34 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[GBT]
Reports for Purchase
Showing records 141 - 160 ( 340 total )
Industry: Medical - Biomedical and Genetics
Oxbryta?/SCD: Submission of MAA to EMA Anticipated by Mid:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Oxbryta/SCD: Updates on Pediatric Label Expansion in the U.S.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Q1 Sales Beat but COVID-19 Slows Q2 Sales but Re- Accelerates in H2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Seven State Physician Survey Tracking Oxbryta Launch; Trends Point to an Above Consensus 1Q
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Sickle Cell Disease KOL Practice
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
In H1, COVID-19 May Slow Oxbryta Launch But We Anticipate H2 Re-acceleration
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
From TINA to Cash Is King and Other Musings
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
KOL: Evolution of Sickle Cell Treatments and He is Prescribing OXBRYTA Now
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L